Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Senator: Everolimus in Senior Renal Transplant Recipients
NCT00956293Phase 4Terminated
- Sponsor
- Novartis
- Start
- Jul 2009
- Primary completion
- Mar 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of everolimus in kidney transplant rejection (2 arms), sponsored by Novartis. Primary endpoint: Renal Function by Glomerular Filtration Rate (GFR) Via Cockcroft-Gault Method at Month 6. Started Jul 2009; status: terminated.
02
Drugs
everolimus
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT00956293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00956293.